Logo

HIND

Vyome Holdings, Inc.

HIND

Vyome Holdings, Inc. • NASDAQ
$5.18 ▲ 0.78% (+0.04)
Market Cap $136.59 M
52w High $583.00
52w Low $4.44
Dividend Yield 0%
P/E -24.67
Volume 3.15K
Outstanding Shares 26.37M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $34.627K ▼ $8.576M ▲ $-8.595M ▼ -24.823K% ▼ $-29.42 ▼ $-8.567M ▼
Q2-2025 $1.242M ▲ $2.65M ▼ $-2.63M ▼ -211.755% ▼ $-9 ▼ $-2.618M ▼
Q1-2025 $1.113M ▼ $2.887M ▼ $1.474M ▲ 132.435% ▲ $9.42 ▲ $-1.835M ▼
Q4-2024 $1.805M ▼ $3.021M ▼ $-1.761M ▼ -97.562% ▼ $-60.31 ▲ $-637K ▲
Q3-2024 $2.292M $3.2M $-1.581M -68.979% $-77.67 $-1.756M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $5.707M ▲ $7.045M ▼ $3.127M ▼ $2.53M ▼
Q2-2025 $4.123M ▲ $9.028M ▲ $3.199M ▼ $5.829M ▲
Q1-2025 $2.515M ▲ $6.483M ▲ $5.253M ▲ $1.23M ▲
Q4-2024 $693K ▼ $4.793M ▼ $5.046M ▲ $-253K ▼
Q3-2024 $743K $5.615M $4.128M $1.487M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-8.434M ▼ $4.342M ▲ $0 $-2.157M ▼ $1.484M ▼ $4.342M ▲
Q2-2025 $-2.63M ▼ $-4.494M ▼ $0 $6.101M ▲ $1.608M ▼ $-4.494M ▼
Q1-2025 $1.474M ▲ $-2.119M ▼ $0 $3.947M ▲ $1.822M ▲ $-2.119M ▼
Q4-2024 $-1.761M ▼ $-687K ▼ $0 $653K ▲ $-50K ▲ $-687K ▼
Q3-2024 $-1.581M $-311K $0 $0 $-310K $-311K

Revenue by Products

Product Q1-2018Q2-2018Q3-2018Q3-2025
License
License
 $0 ▲$0 ▲$0 ▲$0 ▲
Product
Product
 $0 ▲$0 ▲$0 ▲$0 ▲
Royalty
Royalty
 $0 ▲$0 ▲$0 ▲$0 ▲
Product And Service Other
Product And Service Other
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Vyome is essentially a pre‑revenue biotech. Reported sales are negligible and have not grown, so the business is not yet commercially scaled. Operating results show recurring losses each year, consistent with a clinical‑stage company that spends more on research, development, and overhead than it brings in. The extremely volatile reported earnings per share largely reflect repeated reverse stock splits and a tiny equity base rather than swings in the underlying business. Overall, the income statement shows a company still firmly in the investment phase, with no meaningful revenue to offset its costs.

Balance Sheet

Balance Sheet The balance sheet is very thin. Total assets and cash are extremely small and have actually trended down, leaving only a modest cushion to support ongoing operations. Debt appears minimal, which is a positive in terms of leverage, but equity is also very limited and at times close to zero, suggesting a fragile capital structure. The history of frequent and large reverse stock splits points to significant dilution and restructuring over time. In simple terms, Vyome’s financial foundation is light and depends heavily on access to new capital rather than on internally generated strength.

Cash Flow

Cash Flow Cash flow patterns underline the same picture: the company consistently uses cash in its operations, with no offset from a revenue‑generating business. Operating and free cash flows have been negative each year, reflecting spending on R&D and corporate costs. Capital expenditures are negligible, which is typical for an asset‑light biotech focused more on intellectual property than on physical infrastructure. Sustaining the current strategy will likely continue to require external funding or equity issuance, as the business does not yet self‑fund its activities.

Competitive Edge

Competitive Edge Competitively, Vyome is trying to carve out a focused niche rather than compete head‑on with large pharmaceutical companies. Its emphasis on orphan and underserved conditions, dual‑action therapies, and a cross‑border US‑India development model can offer differentiation in terms of speed, cost, and regulatory path. The integration of AI and ties to strong academic institutions add to that edge. However, as a small, pre‑commercial biotech, it faces intense competition for capital, talent, and clinical trial enrollment, and it competes indirectly with larger players that have deeper resources and existing commercial infrastructures.

Innovation and R&D

Innovation and R&D Innovation is the core of Vyome’s story. The company’s platforms for dual‑action drugs and molecular replacement therapies, along with its AI‑driven discovery work and US‑India R&D corridor, are designed to generate differentiated treatments at lower cost. The pipeline spans topical treatments for severe cancer‑related wounds, non‑steroidal eye therapies, and solutions for drug‑resistant acne, all targeting areas with meaningful unmet need. These programs are still in clinical or preclinical stages, so scientific and regulatory risk is high. The stated use of AI and partnerships in medical devices broaden the opportunity but also add execution complexity, especially given the company’s limited financial resources.

Summary

Overall, Vyome is a very early‑stage, innovation‑driven biotech with a promising but unproven pipeline and an ambitious AI‑enabled strategy. Financially, it remains pre‑revenue with persistent losses, a very light balance sheet, and ongoing cash burn, which together make it reliant on external capital. Strategically, its focus on underserved indications, dual‑action therapies, and cost‑efficient cross‑border R&D are clear strengths that could translate into value if clinical and regulatory milestones are met. At the same time, the combination of clinical risk, funding dependence, and small scale means the company’s future path is highly uncertain and sensitive to trial results and financing conditions.

NEWS

November 25, 2025 · 7:00 AM UTC

Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

Read more

November 18, 2025 · 7:00 AM UTC

Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

Read more

November 4, 2025 · 9:04 AM UTC

Vyome Holdings Announces Results of Annual Shareholder Meeting

Read more

September 29, 2025 · 7:00 AM UTC

Vyome Holdings Acquires MIT AI Spinout Oculo Health

Read more

September 17, 2025 · 7:00 AM UTC

Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity

Read more